

Short Note

4,4'-Difluoro-[3,3'-bi(1,2,5-oxadiazole)] 2,2'-Dioxide

Natalia V. Obruchnikova and Oleg A. Rakitin * 

N. D. Zelinsky Institute of Organic Chemistry Russian Academy of Sciences, 47 Leninsky Prospekt, 119991 Moscow, Russia

* Correspondence: orakitin@ioc.ac.ru; Tel.: +7-499-1355327

Abstract: 1,2,5-Oxadiazole oxides (furoxans) are well known nitric oxide donors; among them, 4-fluorofuroxans have recently been found to be important photoinduced nitric oxide donors. In this research, it was shown that the reaction of 4,4'-dinitro-[3,3'-bi(1,2,5-oxadiazole)] 2,2'-dioxide with fluoro-containing reagents (tetrabutylammonium fluoride or cesium fluoride) selectively gave the bis-substitution product 4,4'-difluoro-[3,3'-bi(1,2,5-oxadiazole)] 2,2'-dioxide. The structure of the synthesized compound was established by elemental analysis, ^{13}C , ^{19}F -NMR and IR spectroscopy, and mass-spectrometry.

Keywords: 1,2,5-oxadiazole oxides; 4-fluorofuroxans; nucleophilic substitution; cesium fluoride; tetrabutylammonium fluoride

1. Introduction

Furoxans (1,2,5-oxadiazole oxides) have been intensively investigated [1–3] as compounds that endogenously produce nitric oxide (NO), a gaseous signaling molecule, that mediates a variety of biological effects, such as vasodilation, inhibition of platelet aggregation, cell apoptosis, and neurotransmission [4]. Although many derivatives of this class are described in the literature, the furoxans with photoinduced nitric oxide donor ability are rare [5,6]. Photoinduced nitric oxide donors (PINODs) are used for the spatiotemporal control of the delivery of exogenous NO when light induces otherwise impossible reactivity without remaining in the system after completion. It has been recently found that fluorofuroxans exhibit PINOD character upon isomerization of thermodynamically stable 4-fluorine isomers to 3-isomers by UV irradiation. In the presence of a thiol cofactor as well as in its absence, 3-fluorofuroxans moderately release NO [7,8]. Herein, we report the selective synthesis of 4,4'-difluoro-[3,3'-bi(1,2,5-oxadiazole)] 2,2'-dioxide **1** by the reaction of 4,4'-dinitro-[3,3'-bi(1,2,5-oxadiazole)] 2,2'-dioxide **2** with tetrabutylammonium fluoride or cesium fluoride.

2. Results and Discussion

Treatment of 4,4'-dinitro-[3,3'-bi(1,2,5-oxadiazole)] 2,2'-dioxide **2** with two equivalents of cesium fluoride in MeCN led to a bis-product **1** in a moderate yield of 64% (Scheme 1). The employment of tetrabutylammonium fluoride in THF, according to the reported procedure for 4-nitrofuroxans [8] at room temperature, increased the yield of 4,4'-difluoro-[3,3'-bi(1,2,5-oxadiazole)] 2,2'-dioxide **1** to almost quantitative (93%). We attempted to synthesize monosubstituted 4-fluoro-4'-nitro-[3,3'-bi(1,2,5-oxadiazole)] 2,2'-dioxide. Surprisingly, when using one equivalent of tetrabutylammonium fluoride, a mixture of disubstituted derivative **1** and starting compound **2** is formed; our attempts to isolate the monosubstituted derivative were unsuccessful.

The structure of 4,4'-difluoro-[3,3'-bi(1,2,5-oxadiazole)] 2,2'-dioxide **1** was fully confirmed by elemental analysis, ^{13}C , ^{19}F -NMR and IR spectroscopy, and mass-spectrometry. Elemental analysis confirm the brutto formula of compound **1**. The ^{13}C and ^{19}F -NMR



Citation: Obruchnikova, N.V.; Rakitin, O.A. 4,4'-Difluoro-[3,3'-bi(1,2,5-oxadiazole)] 2,2'-Dioxide. *Molbank* **2023**, *2023*, M1596. <https://doi.org/10.3390/M1596>

Academic Editor: Fawaz Aldabbagh

Received: 3 February 2023

Revised: 16 February 2023


Accepted: 20 February 2023

Published: 23 February 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

spectra of **1** showed characteristic signals for 4-fluorofuroxanes: singlet of ^{19}F (-114.2 ppm), two doublets of 4-F carbon atom 159.5 ($J = 265.5$ Hz), and 3-C carbon atom 93.8 ($J = 31.2$) [8].



Scheme 1. Synthesis of 4,4'-difluoro-[3,3'-bi(1,2,5-oxadiazole)] 2,2'-dioxide **1**.

In conclusion, selective synthesis of 4,4'-difluoro-[3,3'-bi(1,2,5-oxadiazole)] 2,2'-dioxide **1** was developed by the reaction of 4,4'-dinitro-[3,3'-bi(1,2,5-oxadiazole)] 2,2'-dioxide **2** with tetrabutylammonium fluoride in THF or cesium fluoride in MeCN. The compound obtained may be considered as a potential photoinduced nitric oxide donor.

3. Materials and Methods

4,4'-Dinitro-[3,3'-bi(1,2,5-oxadiazole)] 2,2'-dioxide **2** was prepared according to the published method [9]. The solvents and reagents were purchased from commercial sources and used as received. Elemental analysis was performed on a 2400 elemental analyzer (Perkin Elmer Inc., Waltham, MA, USA). Melting point was determined on a Kofler hot-stage apparatus and was uncorrected. ^{13}C and ^{19}F -NMR spectra were taken with a Bruker AM-300 machine (Bruker AXS Handheld Inc., Kennewick, WA, USA) at frequencies of 75 and 282.5 MHz, correspondingly. MS spectrum (EI, 70 eV) was obtained with a Finnigan MAT INCOS 50 instrument (Hazlet, NJ, USA). IR spectrum was measured with a Bruker "Alpha-T" instrument in KBr pellet.

Synthesis of 4,4'-difluoro-[3,3'-bi(1,2,5-oxadiazole)] 2,2'-dioxide **1** (Supplementary Materials).

A solution of tetrabutylammonium fluoride hydrate (560 mg, 2 mmol) in THF (5 mL) was added to a solution of 4,4'-dinitro-[3,3'-bi(1,2,5-oxadiazole)] 2,2'-dioxide **2** (260 mg, 1 mmol) in THF (5 mL). The reaction mixture was stirred for 3 h at room temperature. The solvent was distilled, the residue was extracted with CH_2Cl_2 (2×10 mL), washed with brine, and dried with MgSO_4 . The solvent was removed and the residue was purified by column chromatography on silica gel (Silica gel Merck 60, eluent $\text{CCl}_4/\text{CHCl}_3$, 2:1, v/v). Yield 161 mg (78%), colorless oil, $R_f = 0.78$ ($\text{CCl}_4/\text{CHCl}_3$ 2:1). IR spectrum (KBr), ν , cm^{-1} : 1673 (C=N), 1619, 1556, 1456, 1380, 1178, 959, 819, 778, 674. ^{13}C -NMR (CDCl_3 , ppm): 159.5 (C-4, $J = 265.5$ Hz), 93.8 (C-3, $J = 31.2$ Hz). ^{19}F -NMR (CDCl_3 , ppm): $\delta -114.2$. MS (EI, 70 eV), m/z (I, %): 206 (M⁺, 15), 176 (M⁺—NO, 10), 112 (10), 86 (7), 30 (NO, 100). Anal. calcd. for $\text{C}_6\text{F}_2\text{N}_4\text{O}_4$: C, 23.31; N, 27.19. Found: C, 23.42; N, 27.33%.

A solution of cesium fluoride (304 mg, 2 mmol) in MeCN (3 mL) was added to a solution of 4,4'-dinitro-[3,3'-bi(1,2,5-oxadiazole)] 2,2'-dioxide **2** (260 mg, 1 mmol) in MeCN (3 mL). The reaction mixture was stirred for 3 h at room temperature. The solvent was distilled, the residue was extracted with CH_2Cl_2 (2×10 mL), washed with brine, and dried with MgSO_4 . The solvent was removed and the residue was purified by silica gel column chromatography (Silica gel Merck 60, eluent $\text{CCl}_4/\text{CHCl}_3$, 2:1, v/v). Yield 132 mg (64%), colorless oil.

Supplementary Materials: Copies of ^{13}C , ^{19}F -NMR, IR, and mass-spectra for the compound **1**.

Author Contributions: Conceptualization, N.V.O.; methodology, O.A.R.; software, N.V.O.; validation, O.A.R.; formal analysis, investigation, N.V.O.; resources, O.A.R.; data curation, O.A.R.; writing—original draft preparation, O.A.R.; writing—review and editing, O.A.R.; visualization, O.A.R.; supervision, O.A.R.; project administration, O.A.R.; funding acquisition, O.A.R. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: Samples of the compound **1** are available from the authors.

References

1. Gasco, A.; Fruttero, R.; Sorba, G.; Di Stilo, A.; Calvino, R. NO Donors: Focus on Furoxan Derivatives. *Pure Appl. Chem.* **2004**, *76*, 973–981. [[CrossRef](#)]
2. Fershtat, L.L.; Makhova, N.N. Molecular Hybridization Tools in the Development of Furoxan-Based NO-Donor Prodrugs. *ChemMedChem* **2017**, *12*, 622–638. [[CrossRef](#)]
3. Makhova, N.N.; Fershtat, L.L. 5.05-1,2,5-Oxadiazoles. In *Comprehensive Heterocyclic Chemistry IV*; Elsevier: Amsterdam, The Netherlands, 2022; pp. 190–251. [[CrossRef](#)]
4. Fershtat, L.L.; Zhilin, E.S. Recent Advances in the Synthesis and Biomedical Applications of Heterocyclic NO-Donors. *Molecules* **2021**, *26*, 5705. [[CrossRef](#)]
5. Hwang, K.-J.; Kim, S.K.; Shim, S.C. Photochemical Generation of Nitric Oxide from 3,4-Bis-2'-Chlorophenylfuroxan. *Chem. Lett.* **1998**, *27*, 859. [[CrossRef](#)]
6. Auricchio, S.; Selva, A.; Truscillo, A.M. New Reactions of Furoxans: Formation of Alkynes and Cyclobutaphenanthrenes. *Tetrahedron* **1997**, *53*, 17407–17416. [[CrossRef](#)]
7. Seymour, C.P.; Tohda, R.; Tsubaki, M.; Hayashi, M.; Matsubara, R. Photosensitization of Fluorofuroxans and Its Application to the Development of Visible Light-Triggered Nitric Oxide Donor. *J. Org. Chem.* **2017**, *82*, 9647–9654. [[CrossRef](#)]
8. Ando, A.; Matsubara, R.; Takazawa, S.; Shimada, T.; Hayashi, M. Fluorofuroxans: Synthesis and Application as Photoinduced Nitric Oxide Donors. *Asian J. Org. Chem.* **2016**, *5*, 886–890. [[CrossRef](#)]
9. Larin, A.A.; Shaferov, A.V.; Epishina, M.A.; Melnikov, I.N.; Muravyev, N.V.; Ananyev, I.V.; Fershtat, L.L.; Makhova, N.N. Pushing the Energy-Sensitivity Balance with High-Performance Bifuroxans. *ACS Appl. Energy Mater.* **2020**, *3*, 7764–7771. [[CrossRef](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.